BridgeMD
New treatment option for Parkinson's Disease and Parkinsonism
Official title The Use of the CUE1/CUE1+ in People With Parkinson's Disease and Related Disorders
ClinicalTrials.gov ID: NCT06174948
What this study is testing
- What it's testing
- People with Parkinson's disease (PD) commonly experience a range of both motor (e.g., bradykinesia, rigidity, tremor, and postural instability) and non-motor (e.g., fatigue, psychiatric and behavioural disturbances, autonomic dysfunction, cognitive impairment, sleep dysfunction and olfactory loss) features. Currently, it is challenging to alleviate these symptoms with first-line treatment, the medications such as levodopa.
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Adults over 18 years old
- Clinical diagnosis of idiopathic PD and related disorders including progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal...
- willing to participate and written consent provided after read the participant information sheet.
You likely can't join if
- Individuals with:
- other neurological disorders excluding idiopathic PD, related disorders such PSP, MSA, CBD, and VaP as well as atypical dystonias and tremor...
- metabolic or autoimmune disorders affecting movement, balance and gait
- acute orthopaedic disorders influencing balance control and gait
- audiovestibular disorders including severe hearing loss
- visual disturbances, poor eyesight
See the full eligibility criteria
- Adults over 18 years old
- Clinical diagnosis of idiopathic PD and related disorders including progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal degeneration (CBD), and vascular Parkinsonism (VaP) as well as...
- willing to participate and written consent provided after read the participant information sheet.
- Individuals with:
- other neurological disorders excluding idiopathic PD, related disorders such PSP, MSA, CBD, and VaP as well as atypical dystonias and tremor disorders, affecting movement, balance and gait
- metabolic or autoimmune disorders affecting movement, balance and gait
- acute orthopaedic disorders influencing balance control and gait
- audiovestibular disorders including severe hearing loss
- visual disturbances, poor eyesight
- not able to provide written consent form to participate
- clinical diagnosis of cognitive impairment including dementia or Alzheimer's.
- Mental impairments (illusions, hallucinations, impulse control disorders) (self-reported) Technical contraindications related to CUE1 device:
- implanted metallic or electronic devices usage
- hypersensitivity to vibrotactile stimulation
- skin conditions and/or open wound in the area of where the device will be positioned (e.g., sternum) if taking medicines for PD or related disorder, then on stable dose of treatment for the last three months.
The study team makes the final eligibility decision.
Where it's taking place
- London, United Kingdom
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include London, United Kingdom. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.